FDA Approves ERLEADA — Janssen Products, LP

# FDA Approves Janssen's ERLEADA for Prostate Cancer Treatment Janssen Products, LP received FDA approval for ERLEADA (apalutamide), an oral androgen receptor inhibitor for prostate cancer, positioning the company to compete in the growing non-metastatic castration-resistant prostate cancer market alongside existing therapies from competitors Astellas and Bayer. The approval expands Janssen's oncology portfolio and could capture meaningful market share in a segment projected to see increased patient adoption as awareness of treatment options grows.